Locomotion

New Generation fully wireless VR motion capture device, to dance or physically run in Metaverse

Retrieved on: 
Monday, November 8, 2021
People, SAN, Immersion, Kickstarter, Movement, TRIO, Locomotion, Software, OVR, Solution, VRChat, Head, VR, Dance, Video game console

WalkOVR has been offering its users the easiest and most affordable VR locomotion solutions since the day the company was founded.

Key Points: 
  • WalkOVR has been offering its users the easiest and most affordable VR locomotion solutions since the day the company was founded.
  • This November, they launched their latest product WalkOVR MOCAP updated their software OVR Portal to release their most anticipated feature in VR: Motion capture.
  • It is a well-known fact that motion capture not only brings excitement to the VR gameplay but also doubles up the immersion in the virtual reality environment.
  • You are not just controlling the direction of your VR Avatar, but you can show your dance figures in VR.

uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Monday, October 25, 2021
Safety, Efficiency, Disease, BLA, GRIK2, ESGCT, Spinal cord, Cell, Marketing, Hippocampus, IPSC, Clinical trial, COVID-19, Temporal lobe epilepsy, Gene, Program, Acquisition, D, GLOBE, Locomotion, Liver, Spinocerebellar ataxia, Phase, Research, Neuron, SVB Leerink, Type III, Food, Mirna, Data monitoring committee, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Brain, Annual report, Risk, Company, Hercules, Epilepsy, DSMB, Industry, CSL Behring, TLE, CSL, Sale, Heart, ALS, AAV, C9orf72, Fabry disease, Annual general meeting, Haemophilia, Technology, Huntington's disease, Patient, NASDAQ, FDA, Conference, Kidney, FIX, European Society of Gene and Cell Therapy, Forward-looking statement, Development, Animal, Pharmaceutical industry, Medical device, Vaccine, Cryptocurrency, Reinsurance

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Oct. 25, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2021 and highlighted recent progress across its business.

Key Points: 
  • and AMSTERDAM, The Netherlands, Oct. 25, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2021 and highlighted recent progress across its business.
  • Along with our global partner, CSL Behring, the Company expects to announce top-line data from the HOPE-B trial in the late fourth quarter of 2021.
  • As part of these efforts, the Company anticipates completing the validation of its commercial manufacturing process before year-end 2021.
  • In July 2021, the Company closed the acquisition of Corlieve Therapeutics, a pre-clinical gene therapy company based in France.

uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)

Retrieved on: 
Tuesday, October 19, 2021
ALS, AAV, Nociception, IND, Annual general meeting, GLA, Liver, European Society of Gene and Cell Therapy, NASDAQ, CNS, Neuron, GB3, Technology, Gene, COVID-19, Kidney, Cell, Fabry disease, Haemophilia, Spinal cord, Time, TLE, Type III, CEST, Disease, Epilepsy, Central nervous system, IPSC, Program, Research, C9orf72, Spinocerebellar ataxia, Risk, GLOBE, Brain, Patient, Huntington's disease, Temporal lobe epilepsy, ESGCT, Forward-looking statement, Efficiency, Heart, Phenotype, Locomotion, GRIK2, Pharmaceutical industry, Vaccine

and AMSTERDAM, The Netherlands, Oct. 19, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that four data presentations, including one oral presentation, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) 28th Annual Meeting taking place virtually today through October 22, 2021.

Key Points: 
  • and AMSTERDAM, The Netherlands, Oct. 19, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that four data presentations, including one oral presentation, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) 28th Annual Meeting taking place virtually today through October 22, 2021.
  • AMT-191 is a one-time administered AAV5 gene therapy incorporating an -galactosidase A (GLA) transgene.
  • Moreover, pre-clinical studies in non-human primates with AMT-191 demonstrated robust and sustained increases in GLA activity in multiple organs.
  • uniQure is delivering on the promise of gene therapy single treatments with potentially curative results.

Rare Cannabinoid Company Launches World's First Pure CBDV Oil - Cannabidivarin Is Being Researched For Autism, Muscular Dystrophy, Rett Syndrome and Seizures

Retrieved on: 
Wednesday, September 22, 2021
People, THC, Autism spectrum, Cannabinol, Mouse, Sleep, RATS, Binary relation, Duchenne muscular dystrophy, Weight loss, Hope, Honey, Nervous system, Memory, Social skills, CBN, Inflammation, GW Pharmaceuticals, Cannabinoid, FDA, Locomotion, Map, Patient, Carbon, CBG, THCV, ASD, Physician, Muscular dystrophy, Nausea, CDC, Irritability, Sale, Nursing, Diabetes, CBC, Communication, Glia, Knowledge, CBDV, Growth, Disease, Risk, DMD, Ulcerative colitis, Human, Weight gain, Research, Rett syndrome, CBDA, Paranoia, Anxiety, Relaxation, Seizure, Pharmaceutical industry, Perfume

HONOLULU, Sept. 22, 2021 /PRNewswire-PRWeb/ -- Rare Cannabinoid Company has launched the world's first pure CBDV oil for sale .

Key Points: 
  • HONOLULU, Sept. 22, 2021 /PRNewswire-PRWeb/ -- Rare Cannabinoid Company has launched the world's first pure CBDV oil for sale .
  • While CBDV (cannabidivarin) sounds like CBD (cannabidiol), this varin variety is extremely rare and appears to have exciting potential.
  • In preclinical studies, it has shown potential for easing symptoms of ASD , Rett syndrome and muscular dystrophy .
  • Rare Cannabinoid company's sister brand, Hawaiian Choice , was established in 2017 and is the most popular CBD brand in Hawaii.

Vaccinex CEO, Dr. Maurice Zauderer, Presented New and Promising Phase 2 SIGNAL Trial Data in a Plenary Session at the European Huntington’s Disease Network Meeting

Retrieved on: 
Wednesday, September 15, 2021
People, U.S. Securities and Exchange Commission, Security (finance), European Huntington's Disease Network, Forward-looking statement, Wave, Neurodegeneration, Doctor of Philosophy, Neuron, Patient, Company, Government budget balance, Nasdaq, Disease, Safety, Locomotion, Behavior, Pharmacokinetics, HD, COVID-19, SIGNAL, GLOBE, Cognition, SEMA4D, SEC, Research, Cancer, Pharmaceutical industry, Medical device

Dr. Zauderer highlighted new data from the SIGNAL phase 2 trial believed to further support the cognitive benefit of treatment with the pepinemab antibody.

Key Points: 
  • Dr. Zauderer highlighted new data from the SIGNAL phase 2 trial believed to further support the cognitive benefit of treatment with the pepinemab antibody.
  • People with HD regularly identify cognitive impairment as a major concern that significantly impacts their daily life.
  • Vaccinex is grateful to the individuals and their families who participated in the SIGNAL phase 2 study and remains committed to advancing this promising potential therapy in both HD and Alzheimers disease.
  • Huntingtons disease is an inherited condition that compromises brain functions through progressive damage to neurons and supporting glial cells.

UK's Science Museum Group Turns to Nutanix to Meet Digital Technology Goals  

Retrieved on: 
Tuesday, October 15, 2019
Technology, Human resources, Arts, Museums, Entertainment, Professional services, Software, Other Education, Data management, Education, Science Museum Group, Museums, National museums, England, National Railway Museum, Nutanix, Locomotion, Science Museum, London, Science and Industry Museum, Science museum, County Durham, the Science Museum Group, Eurotech Computer Services, Nutanix

A publicly funded organisation, the SMG includes the historic Science Museum in central London, the National Science and Media Museum in Bradford, Yorkshire, the Science and Industry Museum in Manchester, the National Railway Museum in York and Locomotion in Shildon, County Durham.

Key Points: 
  • A publicly funded organisation, the SMG includes the historic Science Museum in central London, the National Science and Media Museum in Bradford, Yorkshire, the Science and Industry Museum in Manchester, the National Railway Museum in York and Locomotion in Shildon, County Durham.
  • This migration of workloads to Nutanix means the Science Museum Group is ideally placed to harness the potential of digital technology, and we look forward to continuing to work with them on future developments.
  • The Science Museum Group is the worlds leading alliance of science museums, welcoming over five million visitors each year to five sites: the Science Museum in London; the National Railway Museum in York; the Science and Industry Museum in Manchester; the National Science and Media Museum in Bradford; and Locomotion in Shildon.
  • Nutanix, the Nutanix logo, and all Nutanix product and service names are registered trademarks or trademarks of Nutanix, Inc. in the United States and other countries.